Therefore, the synthetic lethality strategy offers an elegant alternative to killing cancer cells with non-druggable mutant tumor suppressor genes and stability genes, for example, TP53 and BRCA1, by targeting their SL partners. This evidence concerns the gene TP53 and cancer.